ESTRO 2025 - Abstract Book

S147

Invited Speaker

ESTRO 2025

4910

Speaker Abstracts Neoadjuvant chemotherapy and chemoradiation Gemma Eminowicz Radiotherapy, University College London Hospital, London, United Kingdom

Abstract:

Chemoradiation has been long established as a curative treatment for locally advanced cervical cancer. Despite improvements in radiotherapy delivery up to 30% of patients can develop recurrent or metastatic disease and therefore adding further systemic therapy to chemoradiation could improve outcomes. Historically induction chemotherapy prior to radiation/chemoradiation has led to mixed results but meta-analyses have suggested that shorter course of platinum dense chemotherapy may be advantageous. The INTERLACE trial was a phase 3 international randomised controlled trial investigating the addition of induction chemotherapy with 6 weeks of carboplatin AUC2 and paclitaxel 80mg/m2 immediately prior to chemoradiation. 70% of patients enrolled had FIGO 2009 IIB disease and 43% had pelvic nodal disease. Patients who received induction chemotherapy had an 8% improvement in progression-free survival at 5 years and a 40% reduction in risk of death compared to those who received chemoradiation alone as well as reduced systemic relapse rate. Grade 3 or more adverse events were increased by 11% and quality of life was in general not significantly impacted with the addition of induction chemotherapy. Radiotherapy treatment was delivered with intensity modulated radiotherapy in 40% and image-guided adaptive brachytherapy in 30% of patients.

This talk will present the efficacy, toxicity, and treatment delivery details from the INTERLACE trial, as well as institutional experience, to argue for its role as standard of care in the treatment of locally advanced cervical cancer.

4912

Speaker Abstracts Current state of the art radiotherapy for sarcoma: Should pre-op radiotherapy be considered a standard of care? Mateusz Spałek Radiotherapy I, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Abstract:

The debate between preoperative and postoperative RT in soft tissue sarcomas continues, particularly with regard to optimizing outcomes while minimizing toxicity. Preoperative RT offers several advantages, including smaller irradiated volume, improved tumor resectability, and reduced long-term fibrosis. However, it also carries risks such as impaired wound healing and surgical complications. This presentation will review the current evidence for sarcoma guidelines, including clinical trials, toxicity profiles, and functional outcomes. We discuss whether preoperative RT should be established as the standard of care based on current data and explore areas for future research to refine patient selection and treatment strategies.